CannSynthesis™ is a novel disruptive technology for the large scale manufacture of pharmaceutically pure cannabinoids including the varin series of compounds. Teewinot has developed a variety of products and services that rely on a powerful array of technologies for the efficient and cost-effective production of authentic cannabinoids, cannabinoid prodrugs and cannabinoid analogs. By combining synthetic biology, biocatalysis, chemical synthesis, bioinformatics and metabolomics, authentic cannabinoids are produced that have the identical chemical structure of cannabinoids found in the Cannabis plant.
Through partnerships with leading universities and pharmaceutical companies, Teewinot is working to move the development of these proprietary compounds into clinics to provide novel therapies. Teewinot has implemented an aggressive intellectual property program to protect these proprietary cannabinoid biosynthesis methods, novel compounds and new therapies.
Teewinot’s in-house Research and Development team utilizes biosynthesis, including synthetic biology and biocatalysis, to cost-effectively produce authentic cannabinoids.
Biosynthesis of Cannabinoids
Instead of producing cannabinoids in the Cannabis plant, Teewinot manufactures authentic cannabinoids that have the same chemical structure of naturally occurring phytocannabinoids by means of patent protected methods that combine the tools of synthetic biology, biocatalysis and chemical synthesis. Teewinot’s proprietary methods of manufacturing authentic cannabinoids are less expensive than growing Cannabis plants and extracting the cannabinoids. In addition, Teewinot’s technology can be used to cost-effectively manufacture cannabinoid prodrugs and cannabinoid analogs that do not naturally occur in the Cannabis plant. Another advantage of these methods is that cannabinoid prodrugs and cannabinoid analogs are produced in highly pure form and without the generation of large amounts of chemical waste associated with multi-step chemical synthesis.
Biocatalysis is a method employed by Teewinot to produce an authentic cannabinoid. A Cannabis cannabinoid biosynthetic gene is first introduced into the genome of a microorganism. The gene is expressed, and produces the encoded enzyme. This cannabinoid biosynthetic enzyme is then used in a biocatalytic process to produce an authentic cannabinoid. The process occurs in a specially designed bioreactor where the enzyme makes contact with its normal substrate and then converts this substrate into an authentic cannabinoid. For example, Teewinot produces the Cannabis enzymes THCA synthase and CBDA synthase in a microorganism. Each enzyme is recovered. THCA synthase converts the substrate CBGA into THCA and/or CBCA in a pH dependent manner in a bioreactor. CBDA synthase converts the substrate CBGA into CBDA and/or CBCA in a pH dependent manner in a bioreactor. The CBGA used in this biocatalytic process can be produced in any number of ways including synthetic biology or chemical synthesis.
Additional proprietary methods for manufacture of cannabinoid prodrugs and cannabinoid analogs also combine synthetic biology, biocatalysis and chemical synthesis. For example, a cannabinoid can be produced by biocatalysis and then chemically modified to produce a final product. A wide range of novel and proprietary cannabinoid prodrugs and cannabinoid analogs can be produced by these methods.
Bioinformatics and Metabolomics
Teewinot has a robust bioinformatics and metabolomics program designed to enhance the company’s cannabinoid production capabilities through gene discovery and sequence analysis. The genes in the Cannabis plant responsible for producing large amounts of cannabinoids are carefully identified and characterized. Chemical compounds produced in cannabinoid-containing plant tissues are identified and quantified through metabolomics. By cloning specific gene sequences from the plant and incorporating them into microorganisms, Teewinot is able to develop new expression systems and processes for production of authentic and specific cannabinoids.